arrow
M

Ming-Lun Yeh

kaohsiung medical university
H指数:35
被引数:4,815

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The Clinical Utility of Adding Laminin Gamma 2 Monomer to the PAGE‐B Score for Hepatocellular Carcinoma Surveillance in Chronic Hepatitis B

在慢性乙型肝炎患者中,将层粘连蛋白γ2单体加入PAGE-B评分以用于肝细胞癌监测的临床应用价值

2026-10-080
PRE
Cardiometabolic Biomarkers for Disease Severity Prediction in Metabolic Dysfunction-Associated Steatotic Liver Disease

代谢功能障碍相关脂肪性肝病中用于疾病严重程度预测的心血管代谢生物标志物

2026-09-130
OAAI
Antiviral therapies are associated with reduced mortality but under-utilized in patients with viral hepatocellular carcinoma: a multinational REAL-HCC study

抗病毒疗法与降低病毒性肝细胞癌患者死亡率相关,但使用率较低:一项跨国REAL-HCC研究

2026-09-110
PRE
Association Between ADH1B rs1229984 Genetic Polymorphism and Hepatic Steatosis Assessed by CT Attenuation: A Mediation Analysis of Central Obesity in MASLD

ADH1B rs1229984基因多态性与CT衰减值评估的肝脂肪变性之间的关联:中央性肥胖在MASLD中的中介分析

2026-09-070
PRE
Prevalence and associated factors of metabolic dysfunction-associated steatotic liver disease in Taiwan, 2001–2021

2001–2021年台湾地区代谢功能障碍相关脂肪性肝病的患病率及其相关因素

2026-07-030
PRE
Impact of Cardiometabolic Risk Factors and Steatotic Liver Disease on Liver-Related Outcomes in Patients With Chronic Hepatitis C After Curative Antiviral Therapy

慢性丙型肝炎患者经治愈性抗病毒治疗后,心血管代谢危险因素和脂肪性肝病对肝脏相关结局的影响

2026-04-220
OAAI
Predictors of fibrosis, clinical events and mortality in MASLD: Data from the Global-MASLD study

Younossi, Z.M.; de Avila, L.; Petta, S.; Hagström, H.; Kim, S.U.; Nakajima, A.; Crespo, J.; Castera, L.; Alkhouri, N.; Zheng, M.H.; 等. MASLD的纤维化、临床事件及死亡率的预测因素:全球MASLD研究的数据. 肝病学 2025. [Google Scholar] [CrossRef]

2025-11-013
PRE
FIB-4 Serves as a Referral Index for Coronary Artery Calcification in Patients With MASLD

FIB-4作为MASLD患者冠状动脉钙化的转诊指数

2025-11-010
PRE
Impact of Concurrent Steatotic Liver Disease and Chronic Hepatitis B on Treatment Response to Nucleos(t)ide Analogs

合并脂肪性肝病和慢性乙型肝炎对核苷(酸)类似物治疗反应的影响

2025-10-010
PRE
Steatotic Liver Disease-Related Polygenetic Risk Score Prediction of Hepatocellular Carcinoma in Nucleotide/Nucleoside Analog-Treated Chronic Hepatitis B

脂肪性肝病相关多基因风险评分对核苷/核苷酸类似物治疗的慢性乙型肝炎患者肝细胞癌的预测

2025-07-240
PRE
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in Taiwan

Sofosbuvir/Velpatasvir治疗对2型糖尿病和慢性丙型肝炎患者肝外表现的影响: 来自台湾全国丙型肝炎病毒登记处的见解

2025-06-200
OAAI
Impact of Hepatitis C Virus Clearance on Cardiovascular Risk: A Real-World Experience From the Nationwide Taiwan Hepatitis C Virus Registry

丙型肝炎病毒清除对心血管风险的影响: 来自全国台湾丙型肝炎病毒登记处的真实经验

2025-05-240
OAAI
Distribution, Characteristics, and Natural History of Diverse Types of Indeterminate Chronic Hepatitis B: A REAL-B Study

不同类型的不确定慢性乙型肝炎的分布、特征及自然史:REAL-B研究

2025-05-210
PRE
Mitochondrial mt12361A>G increased risk of metabolic dysfunction-associated steatotic liver disease among non-diabetes

线粒体mt12361A>G增加非糖尿病患者代谢功能障碍相关的脂肪性肝病的风险

2025-03-140
PRE